Skip to content

Cannabis: all studies

Page 196 of 287: studies 1,951 to 1,960 of 2,864, newest first. Back to the cannabis overview

Research

Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH‐018: a phase 1, placebo‐controlled, pilot study

British Journal of Pharmacology November 22, 2017 Eef L. Theunissen, Nadia R. P. W. Hutten, Natasha L. Mason et al. 38 citations

BACKGROUND AND PURPOSE: Synthetic cannabinoids (often sold as Spice or K2) have become a very popular alternative to cannabis due to their easy access and portrayed safety. Controlled studies on the behavioural effects of synthetic cannabinoids are currently lacking, which hampers risk assessments of these compounds. EXPERIMENTAL APPROACH: This is a first attempt to assess the influence of a...

DOI: 10.1111/bph.14066 (opens in new tab) Cannabis Synthetic cannabinoids Placebo Dosing +4

Synthetic cannabinoids found in "spice" products alter body temperature and cardiovascular parameters in conscious male rats.

Drug and Alcohol Dependence October 1, 2017 Charles W. Schindler, Benjamin R Gramling, Zuzana Justinova et al.

The misuse of synthetic cannabinoids is a persistent public health concern. Because these drugs target the same cannabinoid receptors as the active ingredient of marijuana, Δ9-tetrahydrocannabinol (THC), we compared the effects of synthetic cannabinoids and THC on body temperature and cardiovascular parameters. Biotelemetry transmitters for the measurement of body temperature or blood pressure...

Psychoactive substances as a last resort—a qualitative study of self-treatment of migraine and cluster headaches

Harm Reduction Journal September 4, 2017 Martin Andersson, Mari Persson, Anette Kjellgren 93 citations

BACKGROUND: Treatment resistant cluster headache and migraine patients are exploring alternative treatments online. The aim of this study was to improve comprehension regarding the use of non-established or alternative pharmacological treatments used by sufferers of cluster headaches and migraines. METHODS: A qualitative thematic analysis of the users' own accounts presented in online forum...

Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research

Frontiers in Pharmacology June 21, 2017 Rafael Naime Ruggiero, Matheus Teixeira Rossignoli, Jana Batista de Ross et al. 37 citations

Much of our knowledge of the endocannabinoid system in schizophrenia comes from behavioral measures in rodents, like prepulse inhibition of the acoustic startle and open-field locomotion, which are commonly used along with neurochemical approaches or drug challenge designs. Such methods continue to map fundamental mechanisms of sensorimotor gating, hyperlocomotion, social interaction, and...

DOI: 10.3389/fphar.2017.00399 (opens in new tab) Cannabidiol Cannabis Schizophrenia object-oriented programming Prepulse inhibition +7

New Psychoactive Substances (NPS) – a Challenge for the Addiction Treatment Services

Pharmacopsychiatry April 25, 2017 Norbert Scherbaum, Fabrizio Schifano, Udo Bonnet 46 citations

Over the last few years, hundreds of new psychoactive substances (NPS) have been identified in Europe. Apart from some herbal compounds, NPS mainly include synthetic cannabinoids and a range of new synthetic stimulants (e. g., cathinones). Synthetic NPS are often developed whilst modifying the basic chemical (e. g., phenethylamine or tryptamine) structure. Although the pharmacology and...

DOI: 10.1055/s-0043-102059 (opens in new tab) Cannabis Addiction Synthetic cannabinoids Designer drug +3

New psychoactive substances of natural origin: A brief review

Journal of Food and Drug Analysis April 18, 2017 Ling‐yi Feng, Altansuvd Battulga, Eunyoung Han et al. 86 citations

Plant-based drugs of abuse are as old as recorded human history. Although traditional addictive substances, such as opium, cannabis and coca, have been controlled by the United Nations anti-drug conventions, many, if not most, natural plants with addictive or abuse liability remain elusive. Therefore, the United Nations Office on Drugs and Crime (UNODC) has warned the emerging threat from new...

Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset

CNS & Neurological Disorders - Drug Targets April 17, 2017 Giovanni Martinotti, Rita Santacroce, Duccio Papanti et al. 62 citations

BACKGROUND: Synthetic Cannabinoids (SC) are the widest and most diffused class of Novel Psychoactive Substances. The short- and long- term health risks associated with the consumption of SC are often unknown to both users and health professionals. This review aims to provide a synthesis of the most recent and relevant insights on the pharmacology, clinical and psychopathological aspects of SC....

DOI: 10.2174/1871527316666170413101839 (opens in new tab) Cannabis Synthetic cannabinoids Scopus Psychopathology +1

Aleister Crowley on Drugs

International Journal for the Study of New Religions February 20, 2017 Christopher Partridge 1 citation

While much has been written about the life, work and influence of Aleister Crowley, relatively little attention has been directed to his drug use. This is a little surprising because, not only did he become addicted to heroin, but he incorporated psychoactive substances in his occult work, discussed their psychological effects, commented on drug-related social issues, critiqued contemporary...

Adolescent Cannabinoid Exposure Induces a Persistent Sub-Cortical Hyper-Dopaminergic State and Associated Molecular Adaptations in the Prefrontal Cortex.

Cerebral Cortex February 1, 2017 Justine Renard, Laura G Rosen, Michael Loureiro et al.

Considerable evidence suggests that adolescent exposure to delta-9-tetrahydrocanabinol (THC), the psychoactive component in marijuana, increases the risk of developing schizophrenia-related symptoms in early adulthood. In the present study, we used a combination of behavioral and molecular analyses with in vivo neuronal electrophysiology to compare the long-term effects of adolescent versus...

Combination Chemistry: Structure-Activity Relationships of Novel Psychoactive Cannabinoids.

Current Topics in Behavioral Neurosciences 2017 Jenny L Wiley, Julie A. Marusich, Brian F Thomas

Originally developed as research tools for use in structure-activity relationship studies, synthetic cannabinoids contributed to significant scientific advances in the cannabinoid field. Unfortunately, a subset of these compounds was diverted for recreational use beginning in the early 2000s. As these compounds were banned, they were replaced with additional synthetic cannabinoids with...